Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome today at Clarice Therapeutics' first quarter 2024 conference call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. And to ask a question during the session, you will need to press star 11 on your telephone, and you will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Kevin Balthasar. Please go ahead. Thank you. I am Kevin Balthasar, Chief Financial Officer for Eclaris. Please note that earlier today, we issued a press release highlighting our first quarter 2024 financial results and other business matters. For those of you who have not yet seen it, you will find the release posted under the press releases page of the investor section of our website at www.eclairistx.com. In addition, we will be referring to a slide deck entitled ITK Portfolio, which can be found on the investor presentations page of the investor section of our website and furnished as an exhibit to our Form 8K that we filed with the SEC earlier today. Joining me today for the call are Neil Walker, our interim chief executive officer, and Joe Monahan, our chief scientific officer. Wally Smith, our scientific and business development consultant, will also be available for the Q&A portion of the call. Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the company's future results of operations and financial position, business strategy, and plans and objectives for ACLARIS's future operations are considere...